Uncategorized

Takeda presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura, and pharmacokinetics characteristics of TAK-755, as well as long-term data on TAK-755 prophylaxis from a Phase 3b continuation study.

Results from two studies evaluating the impact of mental health support for diabetes patients found significant benefits in patient outcomes were presented at the 83rd Scientific Sessions of the American Diabetes Association® in San Diego, CA.

Pivotal data from the Phase 3 XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor, Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis in previously treated patients younger than 12 years of age with severe haemophilia A were presented in a late-breaking session at the Annual Meeting of the International Society on Thrombosis and Haemostasis in Montreal, Canada.

Regeneron envisions new dosing for Eylea’s label and it’s the moment of truth for BioMarin’s gene therapy for hemophilia A. For that and more, see inside.

CMS has stated that it will cover new Alzheimer’s drugs if the therapies are fully approved. But significant financial questions remain.

Dexcom, Inc. announced its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego.

Findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced plans to advance its investigational drug LX9211 into late-stage development in a clinical program directed towards an application for regulatory approval in diabetic peripheral neuropathic pain, or DPNP.

The voluntary plan would allow manufacturers to address evidence gaps through studies designed to answer specific questions.

Shareholders are voting on whether to add investor Politan Capital’s picks to the board of the pulse oximeter maker, a move that could change the company’s direction.